Unlock instant, AI-driven research and patent intelligence for your innovation.

Treatment of spasticity with intrathecal dantrolene

A technique for intrathecal administration, side effects, in the field of treatment of spasticity with intrathecal dantrolene

Inactive Publication Date: 2017-02-15
ALLERGAN INC
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Although the therapeutic efficacy of dantrolene in spasticity is generally thought to arise through its direct action on the contractile mechanism of skeletal muscle to reduce contraction force [Pinder et al., 1977; Kheder & Nair, 2012; see also dantrolene FDA "Clinical Pharmacology" section of the approved label], but additional sites of action for dantrolene have not been explored in depth and tested in appropriate animal models

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of spasticity with intrathecal dantrolene
  • Treatment of spasticity with intrathecal dantrolene
  • Treatment of spasticity with intrathecal dantrolene

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0036] The present invention provides a method of treating spasticity in a human subject comprising intrathecally administering to said subject in need of such treatment a therapeutically effective amount of dantrolene or a pharmaceutically acceptable salt thereof.

[0037] As used herein, the terms "intrathecal (IT) administration", "intrathecal injection", "intrathecal delivery" or grammatical equivalents refer to injection anywhere in the spinal canal (the intrathecal space surrounding the spinal cord). In some embodiments, "intrathecal administration" or "intrathecal delivery" according to the present invention refers to IT administration or delivery via the thoracic, lumbar and sacral segments / regions of the spinal cord.

[0038] Salts of dantrolene include pharmaceutically acceptable base addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts. Examples of metal salts include lithium, sodium, potassium, magnesium salts and the like....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is directed to a method of treating spasticity in a human subject, comprising administering intrathecally to the subject a therapeutically effective amount of dantrolene or a pharmaceutically acceptable salt thereof. The administration can be through a chronical drug delivery device such as an intrathecal pump.

Description

[0001] Cross References to Related Applications [0002] This patent application claims priority and benefit to US Provisional Patent Application No. 61 / 912,120, filed December 5, 2013, the disclosure of which is hereby incorporated by reference in its entirety. [0003] field of invention [0004] The present invention relates to a method of treating spastic patients with intrathecally administered dantrolene. [0005] Background of the invention [0006] Spasticity is a common secondary disabling condition following many neurological disorders such as stroke, cerebral palsy, spinal cord injury and multiple sclerosis. It is characterized by increased muscle tone (hypertonia), increased involuntary body reflexes (hyperreflexia), clonus and painful muscle spasms and increased resistance in response to stretching [Kheder & Nair, 2012]. Drug therapy for spasticity is symptomatic with the goal of increasing functional capacity and relieving discomfort. [0007] Dantrolene is an ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4178A61K9/00A61P21/00A61P21/02
CPCA61K9/0085A61K31/4178A61P21/00A61P21/02
Inventor C-J·董
Owner ALLERGAN INC